Table 1. Vaccine protection levels in mice immunized with different BDES constructs following challenge infections administered by the bites of mosquitoes infected with PfCSP-Tc/Pb.
| Vaccine | Delayed parasitemia: no. of uninfected mice/total no. (%)a | Complete protection: no. of protected mice/total no. (%)b | % of mice protectede | ||
| 5 days | 7 days | 9 days | |||
| PBS | 26/40 (65) | 8/40 (20) | 7/40 (18) | 7/40 (18)c | 0.0 |
| AcNPV-WT | 9/15 (60) | 1/15 (7) | 1/15 (7) | 1/15 (7) | 0.0 |
| AcNPV-Dual-PbCSP | 7/10 (70) | 0/10 (0) | 0/10 (0) | 0/10 (0) | −11.1 |
| Adeno-COE/1-373 | 8/10 (80) | 2/10 (20) | 0/10 (0) | 0/10 (0) | −11.1 |
| CMV-full | 15/15 (100) | 8/15 (53) | 7/15 (47) | 7/15 (47)d | 20.0 |
| CAG-full | 36/40 (90) | 21/40 (53) | 16/40 (40) | 16/40 (40)c, d | 26.2 |
| CAG-205 | 38/40 (95) | 25/40 (63) | 19/40 (48) | 19/40 (48)c, d | 30.4 |
Mice were screened for PfCSP-Tc/Pb blood-stage infections by microscopic examination of Giemsa-stained thin smears of tail blood prepared at days 5, 7, 9 and 14 after challenge infections from PfCSP-Tc/Pb-infected mosquitoes (3≤ mosquitoes ≤7/mouse). After the appearance of parasites in the blood, all of the mice died.
Complete protection is defined as the complete absence of blood-stage parasitemia on day 14 post- challenge.
Cumulative data from three independent experiments (Exp. 1, 2 and 3 in Table S1).
Each group of immunized mice were compared with the non-immunized group (PBS) to test for statistically significant differences using Fisher's exact probability test.
Vaccine efficacy was calculated using the formula: Efficacy = [1–[(number of infected animals (I)vaccine/total number of animals (n)vaccine)÷(number of infected animals control (I)/total number of animals (n) control)]]*100. Mean efficacies from three independent studies are shown.